CYP19A1 and prostate carcinoma: The standard of adjuvant endocrine therapy for breast cancer in premenopausal women [41] recommends ovarian suppression therapy tamoxifen or aromatase inhibitors and androgen deprivation therapy (ADT) for prostate cancer patients with antiandrogen drugs.